Enzene Biosciences, a contract development & manufacturing organization (CDMO), launched its first manufacturing site in the U.S., in Hopewell, NJ. The site is expected to be operational in June 2024.

The 54,000 sq.-ft. campus is the first biologics-focused continuous manufacturing base set up by an Indian firm in the U.S.

Himanshu Gadgil, CEO, Enzene Biosciences said, “While the USA is home to most of the novel molecules that are the principal ingredients in creating many life-saving drugs, most of them have been developed by small biotech firms and start-ups that struggle to find clinical phase capacity. Recognizing this gap and driven by our fundamental mission of creating access equity across the global healthcare ecosystem, Enzene Inc. has been launched in the US to establish a state-of-the-art manufacturing plant to cater to small and mid-sized biotech companies.”

Gadgil added, “We have successfully identified, leased, and set up our first manufacturing facility in the states in record time. We remain confident that our proprietary EnzeneX technology platform and proven track record in achieving cost-effective biologics manufacturing will see us emerge as a partner of choice for biotech companies as we support them in bringing promising molecules to market.”